Neuroendocrine tumour – Diagnostics

Go back

Diagnosing neuroendocrine tumours requires a combination of careful physical examination, specialized blood and urine tests, advanced imaging techniques, and tissue analysis. Because these tumours can develop almost anywhere in the body and may grow slowly without causing symptoms for years, identifying them early can be challenging. Understanding the diagnostic process can help you know what to expect and why certain tests are needed.

Introduction: Who Should Seek Diagnostic Testing

Neuroendocrine tumours often remain hidden for long periods because they may not cause noticeable problems until they affect an organ or produce excess hormones. Many people discover they have these tumours by accident during tests for unrelated health issues. However, you should consider seeking medical evaluation if you experience persistent symptoms that don’t improve over time.[1]

Common warning signs include ongoing fatigue, unexplained stomach pain, persistent diarrhea, nausea and vomiting, shortness of breath, or coughing that sometimes includes blood. These symptoms can easily be mistaken for other less serious conditions, which is why they’re often overlooked or attributed to aging or stress. It’s important to remember that having these symptoms doesn’t necessarily mean you have cancer, but they warrant a conversation with your doctor, especially if they persist or worsen.[2]

People with certain inherited conditions face a higher risk of developing neuroendocrine tumours and may benefit from regular monitoring. If you have Multiple Endocrine Neoplasia (MEN)—a rare genetic syndrome that causes tumors to form in various endocrine glands—your doctor may recommend periodic screening. The most common cancer syndrome associated with neuroendocrine tumours is Type 1 MEN (MEN1).[2]

Even if you feel generally well, unexplained weight loss, a distended stomach, or difficulty eating more than a few bites of food could signal a problem worth investigating. Some patients later realize they had been ignoring or dismissing symptoms for months or even years before diagnosis. If something feels persistently wrong with your body, trust your instincts and seek medical advice.[22]

Diagnostic Methods for Identifying Neuroendocrine Tumours

The diagnostic journey for neuroendocrine tumours typically begins with a thorough physical examination. Your healthcare provider will check for visible signs of cancer, such as swollen lymph nodes, and look for evidence that a tumour might be producing excess hormones. They will ask detailed questions about your symptoms, their duration, and any patterns you’ve noticed. This initial assessment helps guide which tests should follow.[10]

Blood and Urine Tests

One of the first steps in diagnosing neuroendocrine tumours involves laboratory testing of blood and urine. Some neuroendocrine tumours produce excessive amounts of hormones, and these can be detected through specialized tests. Your doctor may order blood work to check for elevated hormone levels that could indicate a functioning tumour—one that actively releases hormones into your bloodstream.[10]

Blood tests can also reveal indirect signs of a problem. For example, a patient might show anemia (low red blood cell count) or elevated liver enzymes, which can prompt further investigation. These findings don’t confirm neuroendocrine cancer on their own, but they serve as important clues that something needs closer examination.[22]

Urine tests play a similar role, particularly in detecting certain hormone byproducts that functioning tumours release. The combination of blood and urine analysis helps paint a clearer picture of what might be happening inside your body and whether hormone production is abnormal.[10]

Imaging Studies

Imaging tests create detailed pictures of the inside of your body, allowing doctors to see the location, size, and extent of neuroendocrine tumours. Several different imaging methods may be used, depending on where the tumour is suspected to be located and whether it may have spread to other areas.

Ultrasound uses sound waves to create images of organs and tissues. This non-invasive test is often used to examine the abdomen and can help identify tumours in the pancreas, liver, or other digestive organs. It’s painless and doesn’t involve radiation exposure.[10]

Computerized tomography (CT) scans combine multiple X-ray images taken from different angles to create cross-sectional views of bones, blood vessels, and soft tissues. CT scans provide more detailed information than regular X-rays and can help determine the size of a tumour and whether it has spread to nearby lymph nodes or other organs.[10]

Magnetic resonance imaging (MRI) uses powerful magnets and radio waves to produce detailed images of organs and tissues. MRI scans are particularly useful for examining soft tissues and can provide information that complements what CT scans reveal. Your doctor might order an MRI to get a better look at specific areas of concern.[10]

⚠️ Important
Neuroendocrine tumour cells often have special receptors on their surface that can be targeted for imaging. A specialized PET scan using a tracer that attaches to these receptors provides highly detailed information about where tumour cells are located throughout the body. This type of scan is sometimes called a somatostatin receptor PET scan or dotatate PET scan, named after the tracer medicine used. This advanced imaging technique has significantly improved the ability to detect neuroendocrine tumours that might be missed by conventional imaging methods.

Positron emission tomography (PET) scans represent one of the most important advances in neuroendocrine tumour diagnosis. These scans involve injecting a small amount of radioactive tracer into your vein. The tracer travels through your body and concentrates in areas where tumour cells are present. The PET scanner detects this radioactivity and creates detailed images showing exactly where active tumour cells are located.[10]

The somatostatin receptor PET scan is particularly valuable because many neuroendocrine tumours have receptors for a chemical called somatostatin on their cell surface. The radioactive tracer used in this scan specifically targets these receptors, making it easier to find even small tumours that other imaging methods might miss. This precise detection helps doctors understand the full extent of the disease, including whether it has spread to distant organs.[10]

Biopsy Procedures

A biopsy involves removing a small sample of tissue so it can be examined under a microscope in a laboratory. This is the only way to definitively confirm whether cancer cells are present and to identify the specific type of neuroendocrine tumour you have. The method used to collect the tissue sample depends on where the tumour is located in your body.[10]

Some biopsies can be performed using a needle guided by imaging techniques such as ultrasound or CT scanning. The doctor inserts a thin needle through your skin to reach the tumour and withdraws a small tissue sample. Other situations may require an endoscopy—a procedure where a thin, flexible tube with a camera is inserted through a natural body opening to reach and sample the tumour. For tumours in the digestive tract, this might mean passing the endoscope through your mouth or rectum.[10]

In certain cases, the biopsy may be obtained during surgery, especially if the tumour’s location makes other biopsy methods impractical or if surgery is planned as part of the treatment. Once the tissue sample reaches the laboratory, specialists examine the cells to confirm the diagnosis and gather detailed information about the tumour’s characteristics.[10]

Laboratory Analysis of Tumour Tissue

After a biopsy is performed, laboratory tests analyze the tissue sample to determine critical information about your tumour. Pathologists examine how the cells look under a microscope and perform special tests to measure how quickly the tumour cells are dividing. This information helps classify your tumour into specific grades and types.[6]

The differentiation of tumour cells refers to how much they resemble normal cells. Well-differentiated cells look more like healthy cells and typically grow more slowly, while poorly differentiated cells appear more abnormal and tend to grow faster. Your pathology report will describe the differentiation of your tumour cells.[6]

The grading system for neuroendocrine tumours is based on how fast the cells are growing, measured by counting dividing cells (mitotic count) and using a marker called the Ki-67 index. Tumours are typically classified as Grade 1 (low-grade, slow-growing), Grade 2 (intermediate-grade), or Grade 3 (high-grade, fast-growing). This grading is crucial because it helps predict how the tumour might behave and guides treatment decisions.[6]

The World Health Organization has established a classification system that categorizes neuroendocrine tumours into different groups based on their grade and other characteristics. Well-differentiated neuroendocrine tumours can be further divided into those with benign behavior and those with uncertain behavior. Well-differentiated neuroendocrine carcinomas show low-grade malignant behavior, while poorly differentiated neuroendocrine carcinomas are high-grade and include small cell and large cell types.[6]

Diagnostic Testing for Clinical Trial Qualification

If you’re considering participating in a clinical trial, you’ll need to undergo specific diagnostic tests that serve as standard criteria for enrollment. Clinical trials have strict requirements to ensure that participants have the type and stage of disease being studied and are healthy enough to safely receive the experimental treatment.[14]

Baseline diagnostic tests establish your cancer’s characteristics before any new treatment begins. These typically include comprehensive imaging studies to document the size, location, and extent of all detectable tumours. PET scans, CT scans, and MRI scans create a detailed map of your disease that researchers can compare to future scans to measure whether the treatment is working.[14]

Blood tests are essential for clinical trial screening. Researchers need to verify that your liver, kidneys, and other organs are functioning adequately to handle the trial treatment. They also measure baseline hormone levels if your tumour is the functioning type. Complete blood counts check that you have sufficient red blood cells, white blood cells, and platelets. These tests must show that your overall health meets the trial’s safety requirements.[10]

Tissue samples from your original biopsy may need to be retested or additional biopsies may be required. Many clinical trials, especially those testing targeted therapies, require confirmation that your tumour has specific molecular characteristics or receptors that the experimental treatment is designed to target. For example, trials testing treatments that work through somatostatin receptors need proof that your tumour cells actually have these receptors.[14]

⚠️ Important
Clinical trials offer access to cutting-edge treatments that aren’t yet available outside of research settings. Major cancer centers conduct numerous clinical trials each year, and patients enrolled in these studies may be among the first to benefit from breakthrough therapies. The diagnostic tests required for trial enrollment, while sometimes extensive, ensure that the treatment is appropriate for your specific situation and that researchers can accurately measure its effects.

The grading and staging of your tumour must be precisely documented for clinical trial purposes. Researchers use standardized classification systems to group patients with similar disease characteristics. Your tumour grade (how fast cells are dividing), stage (how far the cancer has spread), and location all factor into determining trial eligibility. These details come from combining results from imaging studies, biopsies, and laboratory analyses.[6]

Some trials require genetic testing of tumour tissue to look for specific mutations or molecular markers. This advanced testing examines the DNA of cancer cells to identify particular genetic changes that might make them respond to targeted treatments. While not all neuroendocrine tumour patients need genetic testing for standard care, it may be mandatory for certain clinical trials investigating precision medicine approaches.[2]

Functional status assessments evaluate your ability to carry out daily activities. Clinical trial protocols often specify that participants must be well enough to care for themselves and spend a certain amount of time out of bed. This isn’t meant to exclude anyone unfairly, but rather to ensure that patients can safely tolerate the experimental treatment and that their health status doesn’t confound the study results.[14]

Regular monitoring through repeated diagnostic tests is a fundamental part of clinical trial participation. Throughout the study, you’ll undergo periodic imaging, blood work, and other assessments at predetermined intervals. These repeated tests track how your tumours respond to treatment, detect any side effects early, and provide the data researchers need to evaluate whether the new therapy is effective.[14]

Prognosis and Survival Rate

Prognosis

The outlook for people with neuroendocrine tumours varies considerably depending on several important factors. The type of neuroendocrine tumour you have, where it’s located in your body, how fast it’s growing (its grade), and whether it has spread beyond its original site all influence what you can expect going forward.[1]

Many neuroendocrine tumours grow slowly and can be controlled for many years, even when they cannot be completely cured. Some are actually curable, particularly when caught at an early stage before spreading. The grade of your tumour—whether it’s classified as Grade 1, 2, or 3—plays a significant role in determining prognosis. Lower-grade tumours that grow slowly generally have better outcomes than high-grade tumours that divide rapidly.[6]

The location of your tumour matters significantly. For instance, pancreatic neuroendocrine tumours tend to grow more slowly than pancreatic adenocarcinomas (a different type of pancreatic cancer) and generally have a better prognosis. Whether your tumour is functional (producing excess hormones) or non-functional also affects your experience with the disease, though both types can often be managed effectively with appropriate treatment.[1]

Early diagnosis and treatment continue to increase the number of people living for years with neuroendocrine tumours. Advances in diagnostic techniques, particularly specialized imaging that can detect even small tumours, mean that more people are being diagnosed earlier when treatment options are most effective. When surgery can completely remove a neuroendocrine tumour at an early stage, it can often be cured. Even when tumours have spread and cannot be surgically removed, the disease and its symptoms can frequently be controlled for extended periods.[2]

Survival rate

Survival statistics for neuroendocrine tumours are generally more favorable compared to many other types of cancer, though they vary widely depending on the specific characteristics of the tumour. It’s important to understand that survival statistics represent averages from large groups of patients and cannot predict exactly what will happen in any individual case.[1]

Many people with neuroendocrine tumours live for many years after diagnosis, particularly those with well-differentiated, low-grade tumours. Even in cases where the tumour has spread to other organs like the liver, patients can often live with the disease for years while receiving treatment that controls tumour growth and manages symptoms. The slow-growing nature of many neuroendocrine tumours means that even advanced disease doesn’t necessarily translate to a poor short-term outlook.[2]

The specific survival rates depend heavily on the tumour’s location and grade. For example, well-differentiated neuroendocrine tumours of the small intestine that are detected early have very good survival rates. Pancreatic neuroendocrine tumours, while serious, generally have better survival outcomes than pancreatic adenocarcinomas. Poorly differentiated, high-grade neuroendocrine carcinomas behave more aggressively and have lower survival rates than their well-differentiated counterparts.[1]

Your doctor is the best person to discuss your individual prognosis. They can consider all the specific details of your situation—your tumour’s type, grade, stage, location, and your overall health—to provide personalized information about what you might expect. Not everyone wants detailed prognostic information, and that’s perfectly acceptable. You should feel comfortable asking questions when you’re ready, or choosing not to know certain details if that’s what feels right for you.[19]

Ongoing Clinical Trials on Neuroendocrine tumour

  • Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors

    Recruiting

    1 1
    France Italy Spain
  • Study on the Effect of Octreotide and Lanreotide in Peptide Receptor Radionuclide Therapy for Adults with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    The Netherlands
  • Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Belgium The Netherlands
  • Study on Personalized vs Non-Personalized Radionuclide Therapy with 177Lu-Edotreotide and Capecitabine for Patients with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Sweden
  • Study of Cabozantinib in Adults with Advanced Low-Grade Neuroendocrine Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany
  • Study on Long-term Safety of Satoreotide Tetraxetan Lutetium-177 for Patients with Somatostatin Receptor Positive Neuroendocrine Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

    Not recruiting

    1 1 1 1
    Investigated diseases:
    France Germany Italy The Netherlands Spain
  • Study on the Safety of Lutetium (177Lu) Oxodotreotide, L-Lysine Hydrochloride, and L-Arginine Hydrochloride in Adolescents with Neuroendocrine Tumors and PPGLs

    Not recruiting

    1 1 1
    Investigated diseases:
    France Poland Spain

References

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/symptoms-causes/syc-20354132

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.mdanderson.org/cancerwise/neuroendocrine-tumors–9-things-to-know.h00-159379578.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC10420169/

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets

https://en.wikipedia.org/wiki/Neuroendocrine_tumor

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/understanding-neuroendocrine-cancer/

https://neuroendocrine.org.au/what-are-nets/

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neuroendocrine-tumor

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/diagnosis-treatment/drc-20465865

https://www.mdanderson.org/cancer-types/neuroendocrine-tumors/neuroendocrine-tumor-treatment.html

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/treatment

https://winshipcancer.emory.edu/cancer-types-and-treatments/neuroendocrine-tumors/treatment.php

https://neuroendocrine.org.au/treatments/

https://pmc.ncbi.nlm.nih.gov/articles/PMC6378464/

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/living-with-neuroendocrine-cancer/

https://netrf.org/old-for-patients/living-with-nets/symptom-management/

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/living-with/coping

https://www.livingwithnets.com/living-with-neuroendocrine-tumours-nets/diet-and-nutrition/

https://www.webmd.com/cancer/neuroendocrine-tumors-feel-better

https://www.mdanderson.org/cancerwise/neuroendocrine-tumors–9-things-to-know.h00-159379578.html

https://www.uchicagomedicine.org/forefront/cancer-articles/2023/september/pancreatic-nets-patient-chris-meyer

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

How long does it take to diagnose a neuroendocrine tumour?

The diagnostic process varies significantly from patient to patient. Some people receive a diagnosis within a few weeks of their first symptoms, while others experience symptoms for months or even years before the tumour is identified. The timeline depends on how obvious your symptoms are, which tests your doctor orders, and whether the tumour is in a location that’s easy to examine. Once suspected, the actual testing process—including blood work, imaging, and biopsy—typically takes several weeks to complete.[1]

Are neuroendocrine tumour diagnostic tests painful?

Most diagnostic tests for neuroendocrine tumours are not painful, though some may cause mild discomfort. Blood and urine tests involve routine sample collection. Imaging tests like CT, MRI, and PET scans are non-invasive and painless, though you need to lie still for extended periods. Biopsies can cause some discomfort, but doctors use local anesthesia or sedation to minimize pain. Endoscopy procedures are typically performed under sedation so you won’t feel pain during the procedure, though you might experience mild soreness afterward.[10]

Can blood tests alone diagnose a neuroendocrine tumour?

No, blood tests alone cannot definitively diagnose a neuroendocrine tumour, though they provide important clues. Blood tests can detect elevated hormone levels suggesting a functioning tumour or reveal abnormalities like anemia or elevated liver enzymes that warrant further investigation. However, only a biopsy—examining actual tumour tissue under a microscope—can confirm the diagnosis and identify the specific type of neuroendocrine tumour. Blood tests are valuable for monitoring known tumours and checking for excess hormone production, but imaging and tissue sampling are necessary for diagnosis.[10]

Why do I need so many different imaging tests?

Different imaging techniques provide complementary information about your tumour. CT scans excel at showing anatomical details and tumour size, MRI scans are particularly good for examining soft tissues, ultrasound is useful for guiding biopsies, and specialized PET scans can detect even tiny tumours throughout your entire body by targeting specific receptors on neuroendocrine tumour cells. Your doctor orders the combination of tests needed to fully understand your tumour’s location, size, characteristics, and whether it has spread. This comprehensive picture is essential for determining the best treatment approach.[10]

What is the most important diagnostic test for neuroendocrine tumours?

While all diagnostic tests contribute important information, the specialized somatostatin receptor PET scan (dotatate PET scan) has become one of the most valuable tools for neuroendocrine tumour diagnosis. This scan specifically targets receptors that most neuroendocrine tumours have, allowing doctors to see the full extent of disease throughout the body with remarkable precision. However, a biopsy remains essential for confirming the diagnosis and determining the tumour grade, which guides treatment decisions. The “most important” test really depends on your specific situation and what information your doctor needs.[10]

🎯 Key takeaways

  • Neuroendocrine tumours often grow silently for years before causing symptoms, making early diagnosis challenging but not impossible with proper medical attention
  • A combination of physical examination, blood and urine tests, advanced imaging, and tissue biopsy is needed to accurately diagnose and characterize these tumours
  • Specialized PET scans that target somatostatin receptors have revolutionized neuroendocrine tumour detection by finding even tiny tumours invisible to conventional imaging
  • The grade of your tumour—determined by examining how fast cells are dividing—significantly influences treatment decisions and outlook
  • People with inherited conditions like Multiple Endocrine Neoplasia Type 1 should discuss regular screening with their doctors due to increased risk
  • Clinical trials require extensive diagnostic testing to ensure participants have the specific disease characteristics being studied and can safely receive experimental treatments
  • Many neuroendocrine tumours grow slowly and can be controlled for years, with some being completely curable when detected early
  • Your care team can tailor the diagnostic approach to your individual situation, so don’t hesitate to ask questions about why specific tests are being ordered